Autonomic Technologies
Executives
10Board of Directors
6Autonomic Technologies Board of Directors
6 Board of directors
Autonomic Technologies has 6 board of directors, including Gilbert Kliman.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Gilbert Kliman | Gil joined InterWest in 1996. As a leader of InterWest’s Healthcare investment team, he invests in a broad array of healthcare opportunities, with a special interest in ophthalmology, digital health, and AI/robotics. Gil pioneered InterWest’s highly successful ophthalmology franchise. He was an early investor in Avedro, Glaukos, LenSx, and IntraLase, category-creating ophthalmic companies that became standard-of-care for eye surgery around the world. As a successful digital health investor, Gil built this important franchise for InterWest over the last twenty years through multiple companies. He led the Series A of Epocrates, the industry-leading first mobile application for physicians, serving on the board through its 2011 IPO, and was the founding institutional investor in Doximity, helping to build it into the leading physician social network engaging over 70% of U.S. physicians with over one million total users. | Autonomic Technologies | |
Joseph Lacob | Mr. Lacob has served as a Director since 2008. Mr. Lacob has been a partner at Kleiner Perkins Caufield & Byers since 1987. He has been closely involved with KPCB’s investments in over fifty life science companies, including the start-up or incubation of a dozen ventures and with KPCB’s medical technology practice, which includes over thirty therapeutic and diagnostic medical device companies. He is part of KPCB’s growing initiative in the fields of greentech and alternative energy. In addition to serving on the Board of Sundrop Fuels, Mr. Lacob also serves on the Board of Directors of two public companies, Align Technology and Orexigen as well as several other privately-held companies, including Ophthonix, NeuroPace, TherOx, Arresto Biosciences and Codon Devices. He received his Bachelor of Science in Biological Sciences from the University of California at Irvine, a MS in Public Health from UCLA and his MBA from the Stanford Graduate School of Business. | Autonomic Technologies | |
Kevin Wasserstein | specializes in investing and building medical device companies at Versant. His work with entrepreneurs spans the earliest seed or concept stage of development through the entire life cycle of the company. </br></br> Kevin has more than eighteen years of venture capital and operating experience in medical device and high technology companies, and currently serves, or has served, in board or advisory roles with companies which include: Acclarent (acquired: Johnson & Johnson), Autonomic Technologies, Cardiac Concepts, LipoSonix (acquired: Medicis), Lutonix, Microfabrica, NeoGuide Systems (acquired: Intuitive Surgical), Rox Medical, Second Sight Medical, St. Francis Medical (acquired: Kyphon) and The Innovation Factory. In addition, he serves as a member of AdvaMed's National Venture Capital Advisory Board, and MDMA's Venture Capital Advisory Group. </br></br> Before joining Versant in 2002, Kevin held a variety of marketing and business development roles at Guidant Corporation. Most recently he served as head of marketing in Guidant's Cardiac Surgery Group, where he led the group's product/market development and launch initiatives. In Guidant's Peripheral and Carotid Group, Kevin developed and launched several first-generation stent and embolic protection devices while leading the carotid stent program's marketing activities. Previously, in Guidant's Compass Business Development Group, Kevin's responsibilities included acquisition, licensing and investment with both private and public medical device companies, and corporate strategy. His operational experience also includes business development at Heartstream, and engineering design and engineering management at Hughes Aircraft Company. </br></br> Kevin holds both Bachelor's and Master's degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University. | Autonomic Technologies | |
Sami Hamadã© | Autonomic Technologies | ||
Sami Hamade | Autonomic Technologies |
Name | Gilbert Kliman | Joseph Lacob | Kevin Wasserstein | Sami Hamadã© | Sami Hamade |
|---|---|---|---|---|---|
Firm | |||||
Work History | Gil joined InterWest in 1996. As a leader of InterWest’s Healthcare investment team, he invests in a broad array of healthcare opportunities, with a special interest in ophthalmology, digital health, and AI/robotics. Gil pioneered InterWest’s highly successful ophthalmology franchise. He was an early investor in Avedro, Glaukos, LenSx, and IntraLase, category-creating ophthalmic companies that became standard-of-care for eye surgery around the world. As a successful digital health investor, Gil built this important franchise for InterWest over the last twenty years through multiple companies. He led the Series A of Epocrates, the industry-leading first mobile application for physicians, serving on the board through its 2011 IPO, and was the founding institutional investor in Doximity, helping to build it into the leading physician social network engaging over 70% of U.S. physicians with over one million total users. | Mr. Lacob has served as a Director since 2008. Mr. Lacob has been a partner at Kleiner Perkins Caufield & Byers since 1987. He has been closely involved with KPCB’s investments in over fifty life science companies, including the start-up or incubation of a dozen ventures and with KPCB’s medical technology practice, which includes over thirty therapeutic and diagnostic medical device companies. He is part of KPCB’s growing initiative in the fields of greentech and alternative energy. In addition to serving on the Board of Sundrop Fuels, Mr. Lacob also serves on the Board of Directors of two public companies, Align Technology and Orexigen as well as several other privately-held companies, including Ophthonix, NeuroPace, TherOx, Arresto Biosciences and Codon Devices. He received his Bachelor of Science in Biological Sciences from the University of California at Irvine, a MS in Public Health from UCLA and his MBA from the Stanford Graduate School of Business. | specializes in investing and building medical device companies at Versant. His work with entrepreneurs spans the earliest seed or concept stage of development through the entire life cycle of the company. </br></br> Kevin has more than eighteen years of venture capital and operating experience in medical device and high technology companies, and currently serves, or has served, in board or advisory roles with companies which include: Acclarent (acquired: Johnson & Johnson), Autonomic Technologies, Cardiac Concepts, LipoSonix (acquired: Medicis), Lutonix, Microfabrica, NeoGuide Systems (acquired: Intuitive Surgical), Rox Medical, Second Sight Medical, St. Francis Medical (acquired: Kyphon) and The Innovation Factory. In addition, he serves as a member of AdvaMed's National Venture Capital Advisory Board, and MDMA's Venture Capital Advisory Group. </br></br> Before joining Versant in 2002, Kevin held a variety of marketing and business development roles at Guidant Corporation. Most recently he served as head of marketing in Guidant's Cardiac Surgery Group, where he led the group's product/market development and launch initiatives. In Guidant's Peripheral and Carotid Group, Kevin developed and launched several first-generation stent and embolic protection devices while leading the carotid stent program's marketing activities. Previously, in Guidant's Compass Business Development Group, Kevin's responsibilities included acquisition, licensing and investment with both private and public medical device companies, and corporate strategy. His operational experience also includes business development at Heartstream, and engineering design and engineering management at Hughes Aircraft Company. </br></br> Kevin holds both Bachelor's and Master's degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University. | ||
Other Seats | Autonomic Technologies | Autonomic Technologies | Autonomic Technologies | Autonomic Technologies | Autonomic Technologies |
Autonomic Technologies Management Team
10 Team Members
Autonomic Technologies has 10 executives. Autonomic Technologies's current Chief Executive Officer, President is Niamh Pellegrini.
Name | Work History | Title | Status |
|---|---|---|---|
Niamh Pellegrini | Chief Executive Officer, President | Current | |
Craig Patterson | Chief Financial Officer | Current | |
Shashidhar Kori | Chief Medical Officer | Current | |
Benjamin D Pless | Chief Executive Officer, President | Former | |
Benjamin Pless | Chief Executive Officer | Former |
Name | Niamh Pellegrini | Craig Patterson | Shashidhar Kori | Benjamin D Pless | Benjamin Pless |
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer, President | Chief Financial Officer | Chief Medical Officer | Chief Executive Officer, President | Chief Executive Officer |
Status | Current | Current | Current | Former | Former |
You May Also Like
Apneon is an early stage medical device company developing devices for the treatment of sleep apnea.
Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.
Neuromonics is an Australian company that has developed an FDA approved device for treatment of tinnitus over a six month process with 2 hours of use per day.
AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.
Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.
Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.